Conference abstract · 21 Oct 2013
Conference abstractPublished 25 Sep 2014
Current directions for process validation according FDA and EMA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
EMA published the EU GMP Annex 15 on ?Qualification and Validation (Feb 2014) and the revision of its process validation guideline (Feb 2014): Guideline on process validation for finished products-information and data to be provided in regulatory submissions, (effective on Aug 2014), with the objective of integrate modern GMP aspects in the guideline: ? Harmonization with the current FDA Guidance on Process Validation. ? Introduction of a validation lifecycle and continued process verification, thus Integration with the ICH Q8, Q9 and Q10 Guidelines ? Incorporation of Process Analytical Technology (PAT), Quality by Design (QbD) and Real Time Release Testing (RTRT). ? Integration of the Annexes to the current Note for Guidance Both agencies addressed a new direction in validation: Validation is now a Life Cycle Process. The focus is on process knowledge and process understanding. Both should be a result of development and verified in routine production. Some aspects and the possibilities for implementation are under discussion ? What disciplines are needed to fulfill new requirements? ? New guidelines are good but, let?s talk about unmatched needs. Are our Quality systems aligned to the new expectations? ? Is the eCTD good enough to present new data? ? Are inspectors ready to evaluate new data? ? Are our Quality Units experienced enough and trained to oversight operations performing under new standards? ? How to practically start working on Knowledge management?
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 31 Aug 2021
A convergence of regulatory policies at FDA and EMA
Conference abstract · 21 Oct 2013
Requirements of drug-drug interaction studies in the USA and Europe based on recent regulatory FDA and EMA guidelines
Conference abstract · 23 Nov 2012
A convergence of regulatory policies at FDA and EMA
Conference abstract · 23 Nov 2012
Comparison of European Medicines Agency (EMA) and Food and Drug Administration (FDA) procedures for evaluating scientific and regulatory issues of clinical studies during the development of medicinal products: Experience
More from this journal
The newest in Journal of Developing Drugs.
Research article · 17 Jul 2026
Effects of a Food-Derived GLP-1 Formula on Endogenous GLP-1 Secretion and Appetite Responses: A Randomized Double-Blind Crossover Study
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Victor Sanchez”

